Optimal norepinephrine-equivalent dose to initiate epinephrine in patients with septic shock

J Crit Care. 2019 Oct:53:69-74. doi: 10.1016/j.jcrc.2019.05.024. Epub 2019 Jun 3.

Abstract

Purpose: The specific norepinephrine dose at which epinephrine should be added in septic shock is unclear. This study sought to determine the norepinephrine-equivalent dose at epinephrine initiation that correlated with hemodynamic stability.

Methods: Septic shock patients receiving both norepinephrine and epinephrine were included in this study. Classification and regression tree analysis was conducted to determine breakpoints in norepinephrine-equivalent dose predicting hemodynamic stability, with two cohorts identified. The primary outcome was hemodynamic stability, and secondary outcomes were shock-free survival, time to achieve hemodynamic stability, and change in SOFA score.

Results: Optimal dose group was identified as initiating epinephrine when norepinephrine-equivalent dose was between 37 and 133 μg/min. A total of 138 and 61 patients were classified in optimal and non-optimal dose groups, respectively. Baseline characteristics were similar between groups except vasopressin use was more frequent in the optimal dose group. More patients in optimal dose group versus non-optimal dose group achieved hemodynamic stability (40 [29%] vs. 9 [14.8%]), absolute risk difference 14.2% [95% CI 2.5-25.9%]; p = .03). On multivariable analysis, initiating epinephrine within the optimal norepinephrine-equivalent dose range was independently associated with higher odds of hemodynamic response (OR 3.06 [95% CI 1.2-7.6]; p = .02). No differences were observed in other secondary outcomes.

Conclusions: Initiation of epinephrine when patients were receiving norepinephrine-equivalent doses of 37-133 μg/min was associated with a higher rate of hemodynamic stability.

Keywords: Epinephrine; Norepinephrine; Sepsis; Septic shock; Vasopressors.

Publication types

  • Observational Study

MeSH terms

  • Aged
  • Drug Therapy, Combination
  • Epinephrine / administration & dosage*
  • Female
  • Hemodynamics / drug effects*
  • Humans
  • Male
  • Middle Aged
  • Neurophysins / metabolism
  • Norepinephrine / administration & dosage*
  • Protein Precursors / metabolism
  • Retrospective Studies
  • Shock, Septic / drug therapy*
  • Shock, Septic / physiopathology
  • Vasoconstrictor Agents / administration & dosage*
  • Vasopressins / administration & dosage
  • Vasopressins / metabolism

Substances

  • AVP protein, human
  • Neurophysins
  • Protein Precursors
  • Vasoconstrictor Agents
  • Vasopressins
  • Norepinephrine
  • Epinephrine